AlphaValue/Baader Europe Cuts Sanofi Price Target After Scrapped Late-Stage Rare Neurological Disease Trial
() -- AlphaValue/Baader Europe reduced its price target for Sanofi (SAN.PA) after the French drugmaker discontinued the late-stage clinical study of riliprubart in chronic inflammatory demyelinating polyneuropathy. "Had Riliprubart cleared regulatory hurdles, it could have been a multi-blockbuster product for Sanofi. A